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STUDY PROTOCOL Open Access
A cluster randomized clinical trial of a
stepped care intervention for depression in
primary care (STEPCARE)- study protocol
Oye Gureje1*, Bibilola Damilola Oladeji1, Ricardo Araya2 and Alan A. Montgomery3
Abstract
Background: Depression constitutes a significant public health burden and is associated is with high level of
individual suffering. Insufficient human and material resources impede the provision of adequate care for persons
with the condition in low- and middle-income countries. It is commonly recognized that, to bridge this treatment
gap, it is essential to integrate the treatment of depression into primary health care system.
Methods/Design: STEPCARE is a two-arm parallel cluster randomized controlled trial to compare a stepped-care
intervention package for depression in primary health care with care as usual in Nigeria. Randomization was conducted
at the level of the participating primary health care clinics, while interventions are delivered to consenting individual
participants who screen positive on the 9-item patient health questionnaire (PHQ-9 score≥ 11) and fulfil the DSM-IV
criteria for major depression. Intervention delivered by trained primary health care workers (PHCW) supported by
general physicians and psychiatrists as needed is in 3 steps determined by response to treatment. Each step consists of
psychological interventions (including psychoeducation, activity scheduling, social network reactivation and problem
solving treatment) offered to all participants and, depending on severity and response, medication. Primary outcome,
assessed at 12 months following recruitment into the trial, is recovery from depression as shown by a PHQ-9 score of
less than 6. Secondary outcomes include changes in disability, quality of life and service utilization assessed at 6 and
12 months.
Discussion: The stepped care model examines the effectiveness of an intervention package for depression in which
the intensity of treatment is determined by the clinical need of the patients. This approach is designed to make the
most efficient use of available resources.
Trial registration: ISRCTN46754188 (ISRTCN registry at isrtcn.com; registered 23 September 2013)
Keywords: Depression, Primary health care, Stepped care
Background
It is estimated that depressive disorders will become the
third most burdensome health problem in low income
countries after HIV/AIDS and perinatal conditions by
2030 [1]. In Nigeria, the 12-month prevalence rates of
depression in the general population is within a range of
1.5-7 % [2]. Studies in primary care show that depression
is a common problem, occurring in up to 10-20 % of
clinic attendees [3, 4]. Depression is strongly associated
with poverty and social disadvantage [5] and is a risk
factor for suicide, majority of which occurs in low and
middle income countries (LMIC) [6]. Even though ef-
fective treatments for depression are available which, if
provided, could alleviate the negative consequences of
depression, a previous study in Nigeria showed that
about four out of five persons with severe mental disor-
ders, particularly depression, had received no treatment
in the previous year and that, among those who did, only
about 10 % received what could be considered as min-
imally adequate treatment [7, 8].
The Nigerian health system, similar to that in most of
sub-Saharan Africa, is characterized by extreme resource
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constraints, both human and material. For example,
there is only about one psychiatrist to a population of
one million people and the few available specialists are
inequitably concentrated in urban settings [9]. It is gen-
erally recognized that a way to minimize the conse-
quences of this specialist manpower constraint is to
integrate mental health (MH) into primary health care
where services are mostly provided by non-physician
primary health care workers (PHCWs). This strategy is
much more likely to be viable and affordable because
these resources already exist, are less expensive, and
offer increased accessibility given that primary care
clinics are closer to where people live. However this
strategy is hampered by several factors: 1) inadequate
training of the PHCWs, 2) lack of structured support
and supervision for their work, and 3) competing duties
[10]. The problem of lack of resources is further com-
pounded by the inefficiency with which the limited avail-
able resources are used. For example, treatments lacking
any evidence are often offered and specialist time and
skill are not efficiently deployed. A new model to ad-
dress the treatment gap for depression must therefore
give prominence to a more efficient way of deploying
existing resources to deliver effective interventions.
Stepped-care models seek to maximize efficiency by
deploying available resources strictly according to needs,
offering greater resources to those with complex or severe
problems [11].
There is now considerable evidence in support of
stepped and collaborative care approaches to expanding
mental health service [12, 13]. In this model, non-
physician PHCWs deliver the bulk of essential mental
health service under the supervision and support of
nurses or physicians and occasionally of more highly
trained mental health specialists, where these are avail-
able. This process, best described as task-sharing, facili-
tates the delivery of evidence-based health care even in
the context of extreme shortage of specialists as seen in
most LMIC. The World Health Organization (WHO)
has produced a set of guidelines, the mental health gap
action programme intervention guide (mhGAP-IG), that
incorporates evidence-based interventions for a list of
priority mental health conditions, including depression,
to aid the management of these conditions in non-
specialist settings [14]. It builds on the well-established
knowledge that primary care providers can be trained to
deliver both psychological and pharmacological interven-
tions for several mental health conditions, while specialists
offer necessary supervision and/or address more difficult or
complex problems. The content of what is needed to scale
up mental health services is therefore generally agreed
upon. However, the mode of delivery of the intervention in
diverse settings still requires empirical exploration in order
to determine the best fit to local health systems.
There has been at least one systematic review of treat-
ments for depression in LMIC [15]. This review shows
that primary care providers can, with physician and
specialist support, deliver effective interventions that
include psychological as well as medication therapies.
However, the studies demonstrating the feasibility of
training primary care providers to deliver effective inter-
ventions for depression have, till date, been conducted
in settings, which even though classified as LMIC, have
better health resources than those existing in most of
Sub-Sahara Africa. For example, a recent study from
Goa, India, describes an effective stepped care approach
in the treatment of common mental disorders in primary
care settings [13]. All the facilities where the study was
conducted had a physician as well as ready access to a
psychiatrist. However, in Nigeria, as in most sub-Sahara
African countries, in primary health care clinics
(PHCCs) most services are provided by non-physician
PHCWs with only sporadic in-house supervision from a
physician. Specifically, in Nigeria, one general physician
supervises an average of 8-15 primary care clinics. Also,
in most of these countries, the few available psychiatrists
are located in major cities, thus making access to them
for support and supervision difficult if not impossible.
The lack of adequate supervision and support for pri-
mary care providers is recognized as one of the major
reasons for the failure of primary care to meet previous
expectations in regard to provision of mental health ser-
vices [10]. It is therefore important to design and study
the effectiveness of an intervention package for depres-
sion that can be delivered almost exclusively by PHCWs
with a feasible and affordable mode of obtaining supervi-
sion and support from physicians and specialists, wher-
ever available.
Methods and design
Aim of the study
The main aim of this study is to test the effectiveness
and cost-effectiveness of a stepped-care intervention
program for depression in adults delivered mostly by
non-physician PHCWs with medical and specialist
supervision and support provided with the use of mo-
bile phones compared to usual care in a randomized
controlled trial.
Design
This study is a two-arm parallel cluster randomized
controlled trial comparing an intervention package for
depression in primary care based on a version of the
mhGAP-IG contextualized and adapted for the extant
Nigerian health system to care as usual. The unit of
randomization is the primary care clinic. As the inter-
vention is designed to be delivered by clinic staff, the
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cluster randomized design was chosen in order to re-
duce the potential risk of contamination within clinics.
Setting
The study is being conducted in Oyo State, Nigeria. The
state has 33 local government areas (LGAs), from which
eleven LGAs (five urban and six rural) were selected for
the study. We included both urban and rural LGAs in
order to capture the diversity of the socioeconomic
profile of the country and because access to medical
treatment differs substantially between these two types
of setting, thus making the demonstration of the
utility of our program potentially more generalizable.
Our sampling frame included all the primary health
care clinics (PHCCs) that have a full complement of
primary care workers and provide a broad range of
clinical services in the eleven LGAs (n = 97). Of these,
52 provided only maternal and child health care and
were excluded and 10 did not consent to participate.
The remaining 35 were randomized to the two arms of
the study, 18 to intervention arm and 17 to the con-
trol arm.
Health care providers in these clinics consist of nurses,
community health officers and community health exten-
sion workers. Each of these categories of providers has a
minimum of two to three years of post-secondary educa-
tion. Supervision for all the clinics in an LGA is pro-
vided by one general practitioner who is designated as
the Primary Health Care Coordinator for the Local
Government.
The study procedures were described to the supervis-
ing physicians in each of the LGAs and to the matrons
or facility managers in each of the clinics. Only clinics
providing explicit consent to participate were random-
ized into the trial.
Randomization
Eligible and consenting primary health care clinics were
stratified by local government area and allocated to
intervention or control arm using a computer-generated
random number sequence. Allocation was conducted by
one of the authors (AAM) using anonymous codes for
clinics and LGAs provided by other members of the re-
search team, in order to avoid any risk of selection bias.
Ethics and research governance
General information about depression is provided to all
consecutive attendees in the waiting area of the clinic by
trained research staff, after which their permission is
sought for the screening interview. Those who screen
positive (PHQ-9 score of 11 and above) have the full
study protocol explained to them and willing partici-
pants sign the consent form.
Full ethical approval to conduct STEPCARE was ob-
tained from the University of Ibadan/University College
Hospital Joint Ethics Committee.
Adherence to Committee’s specifications and approved
protocol is monitored by two independent groups: a
Data Monitoring and Ethics Committee (DMEC) and a
Trial Steering Committee (TSC). Both the DMEC and
TSC conduct regular reviews of the field work, have one
annual scheduled face-to-face meeting and twice yearly
teleconferences. The role of the DMEC is to advise the
TSC on issues relating to safety and ethical conduct of
the study while the TSC has the responsibility of provid-
ing overall oversight for the study, including ensuring its
implementation according to the approved protocol. The
day-to-day implementation of the study is co-ordinated
by the Study Management Team whose members in-
clude all the investigators, a Trial Manager and supervi-
sors. The team meets bi-monthly by teleconference and
annually face-to-face.
Recruitment of participants and eligibility
Consecutive attendees at the selected PHCCs are
approached while waiting to see the health care pro-
viders and are screened for depression using the 9-item
patient health questionnaire (PHQ-9). Those who screen
positive (PHQ-9 score 11 and above) are assessed for
eligibility and invited to take part in the study. All con-
senting adults patients, aged 18 years and above with a
score of 11 or more on PHQ-9 with confirmed DSM-IV
diagnosis of major depression (depression diagnosis is
confirmed using the short form of the Composite
International Diagnostic Interview (CIDI) [16, 17] are
eligible to participate. Patients are ineligible if there is
an immediate need for medical attention, they are
pregnant or nursing mothers, are actively suicidal,
have a history of bipolar or psychotic disorder or of
severe substance dependence. Also ineligible are those
who are unlikely to remain in the neighbourhood over
the following 12 months.
Treatment in the intervention arm
Eligible and consenting patients are handed their PHQ-9
score and directed to see one of the trained PHCWs in
the clinic. The PHCW takes further history to establish
duration of symptoms, presence of any emergency
(medical emergency or suicidality) and determines
what intervention to administer.
The intervention incorporates components of the
WHO mhGAP-Intervention Guide (MHGAP-IG) for de-
pression, contextualized and adapted for the Nigerian
health system [18, 19], and Problem Solving Treatment
(PST) as used successfully in other interventions in
LMIC [20] and in our pilot study [21]. The MHGAP-IG
is designed to facilitate the recognition and management
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of a set of priority mental, neurological, and substance
use (MNS) disorders in non-specialist settings. The depres-
sion module describes approaches for the recognition as
well as the pharmacological and non-pharmacological treat-
ment of depression. Problem solving approaches have
proven to be successful in the treatment of common men-
tal disorders such as depression and anxiety [20].
The intervention is pragmatic, based on a stepped-
care model, and is fully manualized. It is designed to be
delivered in three steps determined by the patient’s score
on the PHQ-9 and response to treatment (See Fig. 1).
All interventions are carried out in the Yoruba language
by health care providers fluent in the language and expe-
rienced in practicing in the locality. The interventions
have been adapted to the local context and tested during
a pilot study [21].
All individuals consenting to the trial receive step 1.
In step 1, participants with PHQ-9 score between 11
and 14 receive only psychological interventions delivered
by the PHCWs while those with PHQ-9 ≥ 15 at baseline
are immediately assessed with the aim of initiating anti-
depressant medication in addition to the psychological
treatment. Antidepressant medication is initiated follow-
ing a discussion of the results of the assessment of the
Fig. 1 Treatment flow chart
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patient by the PHCW with the supervising general phys-
ician, using mobile phone. After 8 weekly sessions, all
participants are re-assessed with the PHQ-9 and those
who have not shown much improvement or whose
symptoms worsen (PHQ-9 > 50 % of baseline score
or ≥11) are moved to step 2. Participants in step 2 who
have not previously been on antidepressant medication
are reviewed in consultation with the GP with a view to
initiating antidepressant medication and those who are
already on medication are similarly assessed by the GP
with a view to modifying medication regime. All partici-
pants who do not improve after this step may have their
cases discussed with a psychiatrist by the GP in the final
step 3 in the sequence covering up to 6 months. The
manual provides full description of each step and the re-
quired clinical decisions. At each visit, the PHCW asks
structured questions to identify participants at risk of
suicide, or who develop adverse reactions to medication.
Such participants are flagged as an emergency and the
GP is contacted immediately for consultation. All super-
vision and consultations with doctors are provided by
mobile phones except when a face-to-face review is
deemed necessary and feasible.
The psychological component of the intervention con-
sists of psychoeducation, reactivation of social network,
and PST. This intervention is delivered in 8 weekly ses-
sions to all participants entering the program regardless
of the need for medication. All sessions are carried out
face-to-face in the clinic. Each session lasts approxi-
mately 30-45 min and are scheduled at times agreeable
to both the patient and the PHCW. The initial session is
dedicated to psychoeducation in which the symptoms of
depression, possible causes and treatments are discussed.
The following 5 sessions are focused on the basics of
PST by working with the patient to identify and explore
solutions to difficulties/problems they are currently fa-
cing. The PST in Session 6 is specifically dedicated to
exploring support through social networks and the last
two sessions are about integrating it all and preparing
for the future.
The first line medication is amitriptyline, which non-
physician primary care providers in Nigeria are autho-
rized to prescribe. Other antidepressants could be pre-
scribed by the GPs for patients who do not improve or
have other contraindications to the use of tricyclic anti-
depressants. PHCWs are expected to consult with the
GP when PHQ-9 denotes severe depression (PHQ score
of 15 and above), there is no improvement at week 8 or
in case of emergencies (e.g. suicidality or serious drug
reaction).
Control arm
Participants in the control clinic receive ‘enhanced usual
care’. Usual care is ‘enhanced’ by the training of the
providers in this arm before the commencement of the
trial on the recognition and management of depression.
Subjects who are recruited in the control clinics are in-
formed of their PHQ-9 scores and advised to show these
to their health care providers. The choice of treatment
offered is left to the discretion of the PHCW and consist
of the usual services normally available in the clinics;
these include antidepressant medications, brief psycho-
therapeutic interventions, medical consultations, or re-
ferral for specialty treatment. Although all these options
are potentially part of usual care, in reality, unstructured
counselling is often all a patient with recognized depres-
sion receives.
Training
Prior to recruitment of patients, providers in the inter-
vention arm received training on the recognition of de-
pression, the delivery of the manualized intervention
package, how to obtain and document support and
supervision received from the GP using mobile phones.
The training consisted of didactic lectures, clinical dem-
onstrations and role plays over a 3-day period. They had
a further 2-day top-up training about a month into the
study to reinforce the acquired skills and review experi-
ence with implementation of the intervention.
Training for the providers in the control arm was con-
ducted separately. They received a 2-day training on the
identification and treatment of depression. This training
was based on the mhGAP-IG but without detailed PST
training or guidelines and procedure for obtaining struc-
tured support and supervision from physicians. That is,
the providers in the control arm were trained in the rec-
ognition and standard treatment of depression, but not
in the use of PST or the implementation of a stepped-
care management approach (see below).
Support and supervision in the stepped-care model
The components and tasks for each treatment session as
well as the clinical decisions and steps are detailed in
manuals and charts provided to the PHCW and primary
care physicians. Mobile telephone lines were provided to
each of the trained PHCW in the intervention clinics
and their supervising GPs and study psychiatrist. These
mobile phone lines are linked in a closed user group net-
work where calls within the network are free to facilitate
consultation. All telephone reviews and consultations
are on as-needed basis, structured, and follow a flow-
chart that proceeds from the PHCWs through to the GP
and to the psychiatrist.
Outcome measures
Primary
The primary outcome is the proportion of patients who
recover from depression at 12 months from entry to the
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trial. Recovery from depression is defined as a PHQ-9
score < 6.
Secondary
Secondary outcomes are assessed at 6 and 12 months
and consist of: 1) change in depression symptoms at
6 months; 2) level of disability as assessed using the
WHO Disability Assessment Scale; [22] 3) Quality of life
as measured using the WHO Quality of Life instrument
[23] and 4) health care utilization, assessed with the
Service Utilization Questionnaire (SUQ), adapted for the
purpose. The SUQ is derived from the Client Service Re-
ceipt Inventory (CSRI) which is designed to collect infor-
mation about the use and costs of health and social
services and other economic impacts such as time of
work due to illness [24, 25]. The unit costs or prices of
these various resource inputs will be based on the results
of a costing analysis which we have conducted in a num-
ber of health facilities in the setting of the trial.
We have used the scales included in this protocol in
our previous studies as well as during our pilot study
and have found them to be acceptable to patients and
sensitive to change [21, 26, 27]. All outcome assessments
are administered in face-to-face interviews at the re-
spondents’ homes by trained interviewers using the
Yoruba versions of the different instruments. The
Yoruba versions were derived by standard protocols of
iterative back translations and have been used in previ-
ous surveys with good psychometric properties. Out-
come assessors are not involved in delivering the
intervention and are rotated between PHCCs to collect
data. We will seek to collect outcome data from every
participant not known to have died at the time of
follow-up and who has not withdrawn consent, regard-
less of compliance with allocated treatment.
Economic evaluation
We plan to carry out an economic evaluation. Using the
SUQ, we will systematically collect resource-use data, in-
cluding any inpatient care, consultations with health
providers, use of drugs and laboratory tests, and also
time and travel costs associated with this service uptake.
We will also collect information on the financing
sources for each of the categories in order to allow for
an estimation of the extent of private, out-of-pocket ex-
penditures incurred by study subjects and their families.
The unit costs or prices of these various resource inputs
will be derived by carrying out costing analysis in a
number of participating health facilities using data col-
lection templates and protocols previously developed
and applied by us.
Since depression and associated disability outcomes
for the stepped care intervention are also expected to
improve significantly, the intervention will 'dominate'
usual care (i.e. better outcomes, less cost). Such a hy-
pothesis negates the need for a power calculation. If,
however, costs turn out to be higher in the intervention
group, bootstrapped incremental cost-effectiveness ra-
tios for PHQ-9 depression and WHO-DAS disability
scores level will be derived. Using the results of the
Nigerian sample of the WHO multi-country survey
study on health and health system responsiveness to
convert WHO-DAS summary score to a health state
preference measure, we will also construct Quality
Adjusted Life Years (QALYs) for both groups, thereby
allowing comparison of this intervention with other evalu-
ations undertaken in Nigeria and elsewhere. Whether
point estimates demonstrate dominance or not, results
will be plotted on a cost-effectiveness plane and presented
as cost-effectiveness acceptability curves in order to
show the probability of the intervention being cost-
effective at a range of 'willingness-to-pay' threshold
levels. We will conduct sensitivity analysis to take
account of uncertainty and imprecision in the mea-
surements, including multiple imputation models for
missing values.
Sample size and power calculation
Previous studies have shown that low to moderate inten-
sity treatment for depression yields effect sizes on a var-
iety of questionnaire-based outcomes of about 0.33
standard deviations, and about 50 % relative advantage
in recovery rate compared to usual care [28]. Experience
from our previous PHC studies as well as from the con-
trol arm of the Chilean trial suggest a recovery rate of
about 30 % for major depression with no active treat-
ment and about 70 % with treatment [29]. For our sam-
ple size estimation, we sought to detect an absolute
difference of 18 percentage points (41 % recovery in
control and 59 % in intervention groups respectively) at
12 months, a difference that we think is both plausible
for this type of intervention and would promote changes
in practice. We assumed an intra-cluster correlation co-
efficient (ICC) of 0.05 based on pilot study data, and col-
lection of the primary outcome for 80 % of participants.
The uninflated sample size requires 131 per arm for ana-
lysis to detect a difference of 59 % vs 41 % (equivalent
odds ratio = 2.1) with 80 % power at the two-sided 5 %
alpha level. We aimed to recruit 90 individuals per
clinic. With 72 per cluster available for the primary ana-
lysis and an ICC of 0.05, the design effect is 4.55, giving
a total number required for analysis of 1190. We there-
fore aimed to recruit 90 individuals from each of 16
clinics initially. As participant recruitment was slower
than anticipated, in March and November, 2014 we re-
cruited and randomised a further 19 clinics, giving a
total of 35 in the study. Participant recruitment started
December 2013 and is still ongoing.
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Data analysis
Individual data is collected and stored electronically
using palmtops programmed to capture information
directly from respondents. This is to ensure accuracy
and security of data collection. All data are kept an-
onymously using codes to identify individuals. Data is
downloaded from palmtops to desktops located in the
central office in Ibadan where it will be cleaned and
stored. These datasets do not contain the allocation sta-
tus of the participants which is kept as a separate file
and only for the trial statistician. Access to the datasets
is possible for members of the research team through a
password-protected entry.
A full statistical analysis plan will be developed before
any data are analyzed. The analysis and presentation of
the trial will be in accordance with CONSORT guide-
lines for cluster randomized trials [30, 31]. The primary
approach for comparative analyses will be to analyze
participants as randomized without imputation of miss-
ing data, and with due emphasis placed on confidence
intervals for the between-arm comparisons. We will use
descriptive statistics to assess balance between the trial
arms at baseline for both clinic and individual partici-
pant characteristics. In order to take appropriate account
of the hierarchical nature of the data, we will use multi-
variable mixed effects regression models to estimate re-
covery from depression at 12 months for intervention
group versus control, adjusting for baseline depression
and LGA as a stratification variable. In a secondary ana-
lysis, we will further adjust for any variables that were
imbalanced between trial arms at baseline. These ana-
lyses will be repeated for secondary outcomes. We will
conduct sensitivity analyses to assess the potential effect
of missing data, and will investigate the effect of adher-
ence with the intervention. We will investigate whether
between-group differences vary over time using data
from all follow-up visits in repeated measures analyses.
We will investigate whether there is any differential
effect of the intervention according to baseline symp-
tom severity (PHQ-9 score <16, ≥16) and duration
(≤3 months, >3 months) by including appropriate inter-
action terms in the primary regression model. Since the
trial is powered to detect overall differences between groups
rather than interactions of this kind, the results will be
interpreted with due caution.
Data analysis will be conducted once all follow-up is
complete. There are no planned interim analyses.
Discussion
This randomized-controlled trial evaluates the effective-
ness of a stepped care intervention model for depression
in primary care compared to enhanced care as usual.
The key strength of this study is the use of a task-sharing
model that relies almost entirely on the capability of non-
physicians PHCWs to deliver an evidence-based interven-
tion, in keeping with the scarcity of specialist mental health
manpower in the country. The stepped care model exam-
ines the effectiveness of an intervention package for depres-
sion in which the intensity of treatment is determined by
the clinical need of the patients.
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